This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Major Hospital In China Purchases Visius Surgical Theatre

- Hospital Expansion Will Highlight Advanced Intraoperative Imaging Suite -

WINNIPEG, March 29, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced the purchase of a VISIUS Surgical Theatre TM by the First Affiliated Hospital of Zhengzhou University in Zhengzhou City, Henan Province in central China.  Zhengzhou University Hospital is one of the largest hospitals in China, with a neurosurgical department ranked in the top 15 in the country.

Kan Quancheng, President of Zhengzhou University Hospital said: "We believe the VISIUS Surgical Theatre is the essential, leading-edge technology that will take us to the next level of research and clinical practice, especially in Neurosurgery.  We are looking forward to working with IMRIS to achieve our goals". Considering the research opportunities, Cheng Jingliang, Chief Radiologist, added: "Not only the ideal solution for Neurosurgery, "The VISIUS Surgical Theatre will provide us with the best available technology platform for new research in the field of intraoperative MR imaging".

The VISIUS Surgical Theatre at Zhengzhou University Hospital features a high-field (3 Tesla) MR scanner that travels on demand on ceiling-mounted rails into a state-of-the-art neurosurgical OR for imaging without ever moving the patient.  When not needed for intraoperative imaging, the scanner remains in the diagnostic room where it can be used for inpatient and outpatient imaging.  With integrated technologies and control systems for imaging, patient-handling and information management, the VISIUS Surgical Theatre will provide unmatched intraoperative vision to the surgeons at Zhengzhou University Hospital, assist their surgical decision-making and enhance precision in their treatment of patients.

Ke Ning, Vice President and General Manager for IMRIS China, commented on the purchase: "It is an honor to be selected by Zhengzhou University Hospital and to be part of the growth of such an important hospital in China".  David Graves, CEO IMRIS, added: "This is our third project in China, and it serves as a reflection of our commitment to this market and our performance as a global provider of image guided therapy solutions".


IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular and cerebrovascular markets and have been selected by leading medical institutions around the world. 


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs